Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Generic · Injection

Mitoxantrone 2 mg/mL injection price what pharmacies pay, and what you should

There is no weekly pharmacy acquisition cost for mitoxantrone 2 mg/ml injection this week. The makers, package codes, recalls and label are below.

What did you pay for mitoxantrone 2 mg/ml injection? Share it.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Supply status: shortages & recalls

No shortage reportedChecked Nov 16, 2026
No ongoing recalls3 recalls on record, latest Oct 19, 2016

Recalls

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

Every manufacturer and package code

3 companies sell mitoxantrone 2 mg/ml injection under 8 package codes (NDCs).

All 8 package codes

A dash means no weekly price for that maker's packages. Which maker your pharmacy stocks usually doesn't change what you pay, but you can ask.

Official label & what changed

Last changedJuly 17, 2025
Version25 of 19
EffectiveJul 14, 2025
Read the label

MitoXANTRONE Injection, USP (concentrate)

This drug has a boxed warning

WARNING

Mitoxantrone Injection, USP (concentrate) should be administered under the supervision of a physician experienced in the use of cytotoxic chemotherapy agents.

Mitoxantrone Injection, USP (concentrate) should be given slowly into a freely flowing intravenous infusion. It must never be given subcutaneously, intramuscularly, or intra-arterially. Severe local tissue damage may occur if there is extravasation during administration. (See ADVERSE REACTIONS, General, Cutaneous and DOSAGE AND ADMINISTRATION, Preparation and Administration Precautions).

NOT FOR INTRATHECAL USE. Severe injury with permanent sequelae can result from intrathecal administration. (See WARNINGS, General)

Except for the treatment of acute nonlymphocytic leukemia, mitoxantrone therapy generally should not be given to patients with baseline neutrophil counts of less than 1,500 cells/mm3. In order to monitor the occurrence of bone marrow suppression, primarily neutropenia, which may be severe and result in infection, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving mitoxantrone.

Cardiotoxicity:

Congestive heart failure (CHF), potentially fatal, may occur either during therapy with mitoxantrone or months to years after termination of therapy. Cardiotoxicity risk increases with cumulative mitoxantrone dose and may occur whether or not cardiac risk factors are present. Presence or history of cardiovascular disease, radiotherapy to the mediastinal/pericardial area, previous therapy with other anthracyclines or anthracenediones, or use of other cardiotoxic drugs may increase this risk. In cancer patients, the risk of symptomatic CHF was estimated to be 2.6% for patients receiving up to a cumulative dose of 140 mg/m2. To mitigate the cardiotoxicity risk with mitoxantrone, prescribers should consider the following:

All Patients:

•

All patients should be assessed for cardiac signs and symptoms by history, physical examination, and ECG prior to start of mitoxantrone therapy.

•

All patients should have baseline quantitative evaluation of left ventricular ejection fraction (LVEF) using appropriate methodology (ex. Echocardiogram, multi-gated radionuclide angiography (MUGA), MRI, etc.).

Multiple Sclerosis Patients:

•

MS patients with a baseline LVEF below the lower limit of normal should not be treated with mitoxantrone.

•

MS patients should be assessed for cardiac signs and symptoms by history, physical examination and ECG prior to each dose.

•

MS patients should undergo quantitative reevaluation of LVEF prior to each dose using the same methodology that was used to assess baseline LVEF. Additional doses of mitoxantrone should not be administered to multiple sclerosis patients who have experienced either a drop in LVEF to below the lower limit of normal or a clinically significant reduction in LVEF during mitoxantrone therapy.

•

MS patients should not receive a cumulative mitoxantrone dose greater than 140 mg/m2.

•

MS patients should undergo yearly quantitative LVEF evaluation after stopping mitoxantrone to monitor for late occurring cardiotoxicity.

For additional information, see WARNINGS and DOSAGE AND ADMINISTRATION.

Secondary Leukemia:

Mitoxantrone therapy in patients with MS and in patients with cancer increases the risk of developing secondary acute myeloid leukemia.

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Questions about mitoxantrone 2 mg/ml injection

Who makes mitoxantrone 2 mg/ml injection?

3 companies: Fresenius Kabi USA, LLC, Hospira, Inc., Meitheal Pharmaceuticals Inc.. See every package code.

Is mitoxantrone in shortage?

No shortage is reported right now. We check every day.

Has mitoxantrone been recalled?

3 recalls on record. Recalls name specific lots - check yours.

What does "pharmacies pay" mean?

It's the national average price retail pharmacies pay wholesalers and makers to buy the drug, from a weekly government survey of pharmacy invoices. It doesn't include the pharmacy's costs of filling a prescription, which is why the fair price adds a margin and a dispensing fee. How we work it out.

Talk about mitoxantrone 2 mg/ml injection

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.